Aliases & Classifications for Breast Adenoid Cystic Carcinoma

MalaCards integrated aliases for Breast Adenoid Cystic Carcinoma:

Name: Breast Adenoid Cystic Carcinoma 12 14
Adenoid Cystic Carcinoma of Breast 12
Adenoid Cystic Breast Carcinoma 69
Mammary Adenocystic Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4877
NCIt 47 C5130
UMLS 69 C1332167

Summaries for Breast Adenoid Cystic Carcinoma

MalaCards based summary : Breast Adenoid Cystic Carcinoma, also known as adenoid cystic carcinoma of breast, is related to congenital hemolytic anemia and fallopian tube squamous cell carcinoma, and has symptoms including pain An important gene associated with Breast Adenoid Cystic Carcinoma is NFIB (Nuclear Factor I B), and among its related pathways/superpathways are Gene Expression and Developmental Biology. The drugs Fentanyl and Pancreatic Polypeptide have been mentioned in the context of this disorder. Affiliated tissues include breast, liver and skin, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and homeostasis/metabolism

Related Diseases for Breast Adenoid Cystic Carcinoma

Diseases related to Breast Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
id Related Disease Score Top Affiliating Genes
1 congenital hemolytic anemia 10.7 KRT5 KRT8
2 fallopian tube squamous cell carcinoma 10.7 KIT KRT5
3 mannose-binding lectin protein deficiency 10.6 KIT PGR
4 olivopontocerebellar atrophy deafness 10.6 KRT5 KRT8
5 pseudounicornuate uterus 10.6 KIT PGR
6 prostaglandin-endoperoxide synthase deficiency 10.5 KRT7 KRT8
7 engraftment syndrome 10.5 KRT7 KRT8
8 thyroid angiosarcoma 10.5 KIT PGR
9 liver angiosarcoma 10.5 KIT PGR
10 trachea adenoid cystic carcinoma 10.5 KRT7 KRT8
11 bartholin's gland benign neoplasm 10.5 ESR1 PGR
12 central nervous system organ benign neoplasm 10.5 ESR1 PGR
13 gallbladder leiomyoma 10.5 ESR1 PGR
14 lung adenoma 10.5 ESR1 PGR
15 cervical adenitis 10.5 KRT5 KRT7
16 clear cell squamous cell skin carcinoma 10.5 KIT KRT7
17 fallopian tube benign neoplasm 10.5 ESR1 PGR
18 paranasal sinus disease 10.5 ESR1 PGR
19 endometrial disease 10.5 KRT5 KRT7
20 dartoic leiomyoma 10.5 ESR1 PGR
21 sebaceous adenoma 10.5 KIT PGR
22 lipid-cell variant infiltrating bladder urothelial carcinoma 10.5 KRT5 KRT7
23 urinary bladder inverted papilloma 10.5 ESR1 PGR
24 deafness, autosomal dominant 8/12 10.5 ESR1 PGR
25 mucoepidermoid esophageal carcinoma 10.5 KRT5 KRT7
26 intestinal perforation 10.5 ESR1 PGR
27 malignant sertoli-leydig cell tumor 10.5 KIT KRT7
28 acantholytic acanthoma 10.5 KRT5 KRT7
29 cribriform carcinoma 10.5 KRT5 KRT8
30 pineal region meningioma 10.4 ESR1 PGR
31 bladder colloid adenocarcinoma 10.4 ESR1 PGR
32 ovarian mesodermal adenosarcoma 10.4 ESR1 PGR
33 endophthalmitis 10.4 ESR1 PGR
34 mucinous adenocarcinoma 10.4 AR KIT
35 female breast axillary tail cancer 10.4 KRT5 KRT7
36 lobular neoplasia 10.4 KRT5 KRT7
37 chest wall lymphoma 10.4 ESR1 PGR
38 berk-tabatznik syndrome 10.4 KRT7 PGR
39 cutaneous mucoepidermoid carcinoma 10.4 ESR1 PGR
40 diffuse lipomatosis 10.4 KRT7 PGR
41 holoprosencephaly 6 10.4 ESR1 PGR
42 acute thyroiditis 10.4 ESR1 PGR
43 synovitis 10.4 ESR1 KRT7
44 malignant biphasic mesothelioma 10.4 KRT7 KRT8
45 retinitis pigmentosa 20 10.4 ESR1 PGR
46 ulceroglandular tularemia 10.4 AR ESR1
47 malignant peritoneal solitary fibrous tumor 10.3 KRT5 KRT7
48 mesenchymoma 10.3 KIT PGR
49 bronchiolo-alveolar adenocarcinoma 10.3 ESR1 KRT7
50 adenoiditis 10.3

Graphical network of the top 20 diseases related to Breast Adenoid Cystic Carcinoma:



Diseases related to Breast Adenoid Cystic Carcinoma

Symptoms & Phenotypes for Breast Adenoid Cystic Carcinoma

UMLS symptoms related to Breast Adenoid Cystic Carcinoma:


pain

GenomeRNAi Phenotypes related to Breast Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.77 KRT5
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.77 KRT5
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.77 KRT5 KRT8
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.77 KRT5
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.77 KRT8
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.77 KRT7
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.77 KRT5 KRT7 KRT8
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.77 KRT7
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.77 KRT7 KRT5
10 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.36 KRT8
11 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.36 KRT7 KRT8 TOP2A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.36 TOP2A
13 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.36 KRT7 KRT8
14 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.36 TOP2A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.36 KRT8
16 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.36 KRT7 KRT8

MGI Mouse Phenotypes related to Breast Adenoid Cystic Carcinoma:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.18 AR EGFR ERBB2 ESR1 EZH2 KIT
2 cardiovascular system MP:0005385 10.17 AR EGFR ERBB2 ESR1 EZH2 KIT
3 cellular MP:0005384 10.16 ESR1 EZH2 KIT KRT7 PGR AR
4 growth/size/body region MP:0005378 10.15 EZH2 KIT KRT5 KRT8 NFIB AR
5 digestive/alimentary MP:0005381 10.14 AR EGFR ERBB2 ESR1 KIT KRT5
6 embryo MP:0005380 10.13 AR EGFR ERBB2 ESR1 EZH2 KIT
7 endocrine/exocrine gland MP:0005379 10.11 ESR1 EZH2 KIT NFIB PGR AR
8 mortality/aging MP:0010768 10.1 KRT5 KRT8 NFIB PGR AR EGFR
9 integument MP:0010771 10.06 AR EGFR ERBB2 ESR1 EZH2 KIT
10 craniofacial MP:0005382 10.02 AR EGFR ERBB2 KIT KRT5 NFIB
11 limbs/digits/tail MP:0005371 9.98 AR EGFR ERBB2 ESR1 KIT KRT5
12 muscle MP:0005369 9.91 AR EGFR ERBB2 ESR1 EZH2 KIT
13 neoplasm MP:0002006 9.87 KIT PGR AR EGFR ERBB2 ESR1
14 no phenotypic analysis MP:0003012 9.73 EGFR ESR1 EZH2 KIT KRT5 PGR
15 normal MP:0002873 9.7 AR EGFR ERBB2 ESR1 EZH2 KIT
16 reproductive system MP:0005389 9.5 AR EGFR ERBB2 ESR1 KIT KRT8
17 skeleton MP:0005390 9.17 AR EGFR ERBB2 ESR1 EZH2 KIT

Drugs & Therapeutics for Breast Adenoid Cystic Carcinoma

Drugs for Breast Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
3
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
4 Liver Extracts Phase 3,Phase 1
5 Adjuvants, Anesthesia Phase 3
6 Analgesics Phase 3
7 Analgesics, Opioid Phase 3
8 Anesthetics Phase 3
9 Anesthetics, General Phase 3
10 Anesthetics, Intravenous Phase 3
11 Central Nervous System Depressants Phase 3
12 Narcotics Phase 3
13 Peripheral Nervous System Agents Phase 3
14 Antimitotic Agents Phase 3,Phase 2,Phase 1
15 Cola Nutraceutical Phase 3,Phase 1,Phase 2
16
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
17 Immunosuppressive Agents Phase 2,Phase 1
18 Androgens Phase 1, Phase 2
19 Anti-Infective Agents Phase 2,Phase 1
20 Antimetabolites Phase 2,Phase 1
21 Antimetabolites, Antineoplastic Phase 2,Phase 1
22 Antiviral Agents Phase 2,Phase 1
23 Imatinib Mesylate Phase 2 123596
24 Protein Kinase Inhibitors Phase 2,Phase 1
25 Fluorides Phase 1, Phase 2
26 Fluorodeoxyglucose F18 Phase 1, Phase 2
27 Radiopharmaceuticals Phase 1, Phase 2
28
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
29
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904
30
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
31
Trastuzumab Approved, Investigational Phase 1 180288-69-1 9903
32
Pemetrexed Approved, Investigational Phase 1 150399-23-8, 137281-23-3 446556 60843
33
Lenograstim Approved Phase 1 135968-09-1
34
Capecitabine Approved, Investigational Phase 1 154361-50-9 60953
35
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
36
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
38
leucovorin Approved, Nutraceutical Phase 1 58-05-9 143 6006
39
7-hydroxystaurosporine Experimental Phase 1 112953-11-4 72271
40
Camptothecin Experimental Phase 1 7689-03-4
41 Staurosporine Experimental Phase 1 62996-74-1
42
tipifarnib Investigational Phase 1 192185-72-1 159324
43
Silicon Investigational Phase 1 7440-21-3 4082203
44 Antineoplastic Agents, Phytogenic Phase 1
45 topoisomerase I inhibitors Phase 1
46 Topoisomerase Inhibitors Phase 1
47 Adjuvants, Immunologic Phase 1
48 Albumin-Bound Paclitaxel Phase 1
49 Angiogenesis Inhibitors Phase 1
50 Angiogenesis Modulating Agents Phase 1

Interventional clinical trials:

(show all 28)

id Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
3 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
4 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
5 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2 gemcitabine
6 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
7 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
8 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
9 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1 docetaxel
10 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1 alvespimycin hydrochloride
11 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
12 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
13 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Completed NCT01172028 Phase 1 Taxotere (Docetaxel);Alimta (Pemetrexed)
14 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
15 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
16 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1 capecitabine;cisplatin
17 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
18 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
19 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
20 Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin Terminated NCT00023790 Phase 1 silicon phthalocyanine 4
21 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
22 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733 cyclophosphamide
23 Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer Completed NCT00897793
24 Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema Completed NCT00828516
25 Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871 Completed NCT01015963
26 Family Quality of Life Among Families With a Member Who is a Cancer Patient Completed NCT00544336
27 Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer Completed NCT00002520 nicotine
28 Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor Terminated NCT01096381

Search NIH Clinical Center for Breast Adenoid Cystic Carcinoma

Genetic Tests for Breast Adenoid Cystic Carcinoma

Anatomical Context for Breast Adenoid Cystic Carcinoma

MalaCards organs/tissues related to Breast Adenoid Cystic Carcinoma:

39
Breast, Liver, Skin, Salivary Gland, Kidney

Publications for Breast Adenoid Cystic Carcinoma

Articles related to Breast Adenoid Cystic Carcinoma:

id Title Authors Year
1
Breast adenoid cystic carcinoma: report of a case with emphasis on routine sonographic findings and shear wave elastography. ( 28382475 )
2017
2
Breast Adenoid Cystic Carcinoma: A Rare Case Report and Review of the Literature. ( 28798006 )
2017
3
MYB Labeling by Immunohistochemistry Is More Sensitive and Specific for Breast Adenoid Cystic Carcinoma than MYB Labeling by FISH. ( 28498281 )
2017
4
Cutaneous Metastasis of Breast Adenoid Cystic Carcinoma to the Scalp. ( 26968987 )
2016
5
Breast adenoid cystic carcinoma in a 19-year-old man: a case report and review of the literature. ( 25885366 )
2015
6
18F-FDG PET/CT Imaging of Bilateral Renal Metastasis of Breast Adenoid Cystic Carcinoma. ( 26562575 )
2015
7
Male breast adenoid cystic carcinoma. ( 24403896 )
2013
8
Clinical review--breast adenoid cystic carcinoma. ( 22154460 )
2012

Variations for Breast Adenoid Cystic Carcinoma

Cosmic variations for Breast Adenoid Cystic Carcinoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM25159 PTEN breast,NS,carcinoma,adenoid cystic carcinoma c.254-3C>T p.? 10
2 COSM27376 PIK3CA breast,NS,carcinoma,adenoid cystic carcinoma c.93A>G p.I31M 10
3 COSM476 BRAF breast,NS,carcinoma,adenoid cystic carcinoma c.1799T>A p.V600E 10
4 COSM467 BRAF breast,NS,carcinoma,adenoid cystic carcinoma c.1781A>G p.D594G 10
5 COSM449 BRAF breast,NS,carcinoma,adenoid cystic carcinoma c.1391G>A p.G464E 10

Expression for Breast Adenoid Cystic Carcinoma

Search GEO for disease gene expression data for Breast Adenoid Cystic Carcinoma.

Pathways for Breast Adenoid Cystic Carcinoma

Pathways related to Breast Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 AR EGFR ERBB2 ESR1 EZH2 KIT
2
Show member pathways
13.08 EGFR ERBB2 EZH2 KIT KRT5 KRT7
3 12.37 AR EGFR ERBB2 KIT
4
Show member pathways
12.09 AR EGFR ERBB2 ESR1 KIT PGR
5 11.89 AR EGFR ESR1
6
Show member pathways
11.85 AR EGFR ERBB2
7 11.82 EGFR ERBB2 KIT
8
Show member pathways
11.67 KRT5 KRT7 KRT8
9
Show member pathways
11.56 AR ESR1 PGR
10 11.36 EGFR ERBB2 KIT
11
Show member pathways
11.29 EGFR ERBB2 ESR1 PGR
12
Show member pathways
10.99 AR ESR1 NFIB
13
Show member pathways
10.89 EGFR ERBB2 ESR1 KIT

GO Terms for Breast Adenoid Cystic Carcinoma

Cellular components related to Breast Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.7 AR EGFR ERBB2 ESR1 EZH2 KRT5
2 cytoplasm GO:0005737 9.36 AR EGFR ERBB2 ESR1 EZH2 KIT
3 keratin filament GO:0045095 9.33 KRT5 KRT7 KRT8

Biological processes related to Breast Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.88 AR EGFR ESR1 NFIB PGR TOP2A
2 protein autophosphorylation GO:0046777 9.79 EGFR ERBB2 KIT
3 peptidyl-tyrosine phosphorylation GO:0018108 9.78 EGFR ERBB2 KIT
4 transcription initiation from RNA polymerase II promoter GO:0006367 9.77 AR ESR1 PGR
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.76 EGFR ERBB2 KIT
6 cornification GO:0070268 9.75 KRT5 KRT7 KRT8
7 phosphatidylinositol-mediated signaling GO:0048015 9.73 EGFR ERBB2 KIT
8 male gonad development GO:0008584 9.72 AR ESR1 KIT
9 phosphatidylinositol phosphorylation GO:0046854 9.7 EGFR ERBB2 KIT
10 response to estradiol GO:0032355 9.69 EGFR ESR1 EZH2
11 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.61 EGFR ERBB2 KIT
12 mammary gland alveolus development GO:0060749 9.59 AR ESR1
13 negative regulation of ERBB signaling pathway GO:1901185 9.57 EGFR ERBB2
14 steroid hormone mediated signaling pathway GO:0043401 9.54 AR ESR1 PGR
15 positive regulation of transcription from RNA polymerase III promoter GO:0045945 9.49 AR ERBB2
16 protein localization to chromatin GO:0071168 9.48 ESR1 EZH2
17 positive regulation of phospholipase C activity GO:0010863 9.46 ESR1 KIT
18 regulation of transcription from RNA polymerase II promoter GO:0006357 9.43 AR EGFR ERBB2 ESR1 EZH2 KIT
19 signal transduction by protein phosphorylation GO:0023014 9.32 ERBB2 KIT
20 morphogenesis of an epithelial fold GO:0060571 9.26 AR EGFR
21 tongue development GO:0043586 9.24 EGFR
22 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.16 AR PGR
23 positive regulation of MAP kinase activity GO:0043406 8.92 EGFR ERBB2 EZH2 KIT

Molecular functions related to Breast Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 9.83 AR ESR1 NFIB PGR
2 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.8 AR ESR1 NFIB PGR
3 protein tyrosine kinase activity GO:0004713 9.71 EGFR ERBB2 KIT
4 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.69 EGFR ERBB2 KIT
5 ATPase binding GO:0051117 9.65 AR ESR1 PGR
6 chromatin binding GO:0003682 9.65 AR EGFR ESR1 EZH2 TOP2A
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.63 EGFR ERBB2 KIT
8 steroid hormone receptor activity GO:0003707 9.58 AR ESR1 PGR
9 enzyme binding GO:0019899 9.55 AR EGFR ESR1 PGR TOP2A
10 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.54 EGFR ERBB2 KIT
11 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.5 AR ESR1 PGR
12 nitric-oxide synthase regulator activity GO:0030235 9.43 EGFR ESR1
13 steroid binding GO:0005496 9.13 AR ESR1 PGR
14 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 8.8 EGFR ERBB2 KIT

Sources for Breast Adenoid Cystic Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....